KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Deferred Taxes: 2017-2023

Historic Deferred Taxes for BeOne Medicines (ONC) over the last 7 years, with Dec 2023 value amounting to -$46,000.

  • BeOne Medicines' Deferred Taxes fell 102.74% to -$46,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $689,000, marking a year-over-year decrease of 66.54%. This contributed to the annual value of $26.0 million for FY2024, which is 3671.12% up from last year.
  • Per BeOne Medicines' latest filing, its Deferred Taxes stood at -$46,000 for Q4 2023, which was down 106.13% from $750,000 recorded in Q3 2023.
  • BeOne Medicines' 5-year Deferred Taxes high stood at $14.8 million for Q3 2021, and its period low was -$12.3 million during Q1 2021.
  • Its 3-year average for Deferred Taxes is $510,417, with a median of $43,000 in 2022.
  • As far as peak fluctuations go, BeOne Medicines' Deferred Taxes slumped by 5,847.09% in 2021, and later soared by 941.67% in 2022.
  • Over the past 5 years, BeOne Medicines' Deferred Taxes (Quarterly) stood at $4.1 million in 2019, then skyrocketed by 119.97% to $9.0 million in 2020, then crashed by 89.99% to $903,000 in 2021, then surged by 85.94% to $1.7 million in 2022, then crashed by 102.74% to -$46,000 in 2023.
  • Its Deferred Taxes stands at -$46,000 for Q4 2023, versus $750,000 for Q3 2023 and -$51,000 for Q2 2023.